Catalyst Wire Dossier Catalyst Wire Dossier

Vabysmo (faricimab)

faricimab · Genentech, Inc.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Vabysmo (faricimab), covering 2026-03-30 to 2026-03-30. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema [Phase 1, Phase 2]

See pricing